Heartseed has set a mission to “open the door to heart disease treatment with regenerative medicine”.
Heartseed has set a mission to “open the door to heart disease treatment with regenerative medicine” and is working toward the day-to-day clinical application of myocardial regenerative medicine.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 11, 2021 | Series C | $37M | 9 | — | — | Detail |
| Mar 10, 2020 | Corporate Round | ¥100.34M | 2 | — | — | Detail |
| Nov 21, 2019 | Series B | $26M | 6 | — | — | Detail |
| Jul 30, 2018 | Series A | ¥800M | 3 |
Angel Bridge
|
— | Detail |
| Mar 14, 2016 | Seed | ¥100M | 1 |
Angel Bridge
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Angel Bridge
|
Yes | Series A |
ITOCHU Chemical Frontier
|
— | Series C |
Keio Innovation Initiative
|
— | Series C |
Medical Incubator Japan
|
— | Series C |
Medipal Holdings
|
— | Series C |
Nissay Capital
|
— | Series C |
SBI Group
|
— | Series C |
SMBC Venture Capital
|
— | Series C |
Sumitomo Mitsui Trust Investment
|
— | Series C |
UTokyo Innovation Platform
|
— | Series C |